Gara Jalqabaatti › Kansa Mataa fi Morma › Kentucky
Qorannoo klinikaalii Kansa Mataa fi Morma Kentucky keessatti
Qorannoo 5 Kansa Mataa fi Morma f Kentucky keessatti hirmaatuu jiru.
Magaalota Kentucky keessatti
Takkalaa qorannoo (Ingiliffa)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- University of Kentucky, Markey Cancer Center (Site # 109), Lexington
- Site#0111, Louisville
- Site#0115, Louisville
Namoota walitti qabaa jiraSadarkaa 2/3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06788990Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Norton Cancer Institute, Louisville
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 29-Ado-2026 · NCT04198766Lead-212 PSV359 Therapy for Patients With Solid Tumors
- University of Kentucky, Lexington
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 90 · Saalaa hunda · Haaromfame 06-Ado-2026 · NCT06710756A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Lexington
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 26-Cam-2026 · NCT06256588cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Baptist Corbin, Corbin
- Baptist Hardin, Elizabethtown
- Baptist Lexington, Lexington
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 40 fi ol · Saalaa hunda · Haaromfame 20-Ama-2026 · NCT05366881Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.